Interpretative Differences of Combined Cytogenetic and Molecular Profiling Highlights Differences Between MRC and ELN classifications of AML

Prognosis of newly diagnosed acute myeloid leukemia (AML) is largely dependent on genetic features that are revealed through karyotype analysis. Roughly half of all diagnostic karyotypes demonstrate a chromosomal aberration that can be used to assess prognosis [1]. With the addition of sub-karyotypic mutations, AML includes a considerable number of unique malignancies and can even include heterogeneous clonal populations [2, 3]. There are a number of different prognostic categorization schemes for AML including those from the World Health Organization (WHO) [4], the National Comprehensive Cancer Network (NCCN) [5], Southwest Oncology Group (SWOG) [6], UK National Cancer Research Institute Adult Leukaemia Working Group (Medical Research Council, MRC)[1, 7], European Leukemia Net (ELN)[8, 9] and the Cancer and Leukemia Group B (CALGB)[10].
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research